ORPHA:732
Polymyositis
Publications
18,613
Trials
45
Interventional, condition-specific
Researchers
1,264
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare inflammatory (IIM) historically characterized by symmetric proximal muscle weakness, elevated muscle enzymes (creatine kinase), myopathic findings on electromyography, and muscle biopsy showing endomyial infiltration composed mainly of macrophages and lymphocytes. The features are non-specific, thus the disease should be distinguished from similar entities with specific clinical, immunological, histological features, notably dermatomyositis, immune-mediated necrotizing , anti-synthetase syndrome, inclusion body myositis, and myositis associated with other connective tissue disorder.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019127
- MeSH:D017285
- UMLS:C0085655
- NCIT:C26925
Additional Mondo synonyms (2)
PM · polymyositis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
18,613 matched papers (8,437 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
45 matched on ClinicalTrials.gov (10 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
18,613
18,613 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
18,613 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
8,437 in the last 10 years · low confidence
Phrase hits: 18,613 · MeSH hits: 0
Who's working on it?
1,264
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li M5 papers · 2026
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China. Electronic address: mengtao.li@cstar.org.cn.
Papers in Europe PMC - 02Li Z5 papers · 2026
Department of Pharmacy, Dalian Women and Children's Medical Center (Group), Dalian, China.
Papers in Europe PMC - 03Aggarwal R3 papers · 2026
Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. aggarwalr@upmc.edu.
Papers in Europe PMC - 04Chang YS3 papers · 2026
Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taipei Medical University, Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan risea65@gmail.com.
Papers in Europe PMC - 05Che WI3 papers · 2026
Department of Public Health and Medicinal Administration, Faculty of Health Sciences, University of Macau, Macau SAR, China.
Papers in Europe PMC - 06Chen Y3 papers · 2026
Department of Medical Imaging, the First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, Shaanxi 710061, PR China (K.Y., Y.C., L.H., Y.S., H.H., J.Z., C.J.).
Papers in Europe PMC - 07Holmqvist M3 papers · 2026
ME Gastro, Derm and Rheuma, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden; Division of clinical epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. Electronic address: marie.holmqvist@ki.se.
Papers in Europe PMC - 08Kao JH3 papers · 2026
Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taipei Medical University, Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan.
Papers in Europe PMC - 09Lee IP3 papers · 2026
Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taipei Medical University, Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan.
Papers in Europe PMC - 10Li H3 papers · 2026
Department of Rheumatology and Immunology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
45
interventional trials for this specific condition
45 interventional trials matched this specific condition name; 10 currently recruiting in our sample.
Data as of 27 July 2026
45 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 96.8th percentile).
low confidence · 96.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
45 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07160205·RECRUITING·Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Conditions: Idiopathic Inflammatory Myositis (IIM) · DERMATOMYOSITIS OR POLYMYOSITIS·Matched via name phrase
- NCT05895786·RECRUITING·A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Conditions: Myositis·Matched via name phrase
- NCT05979441·ENROLLING BY INVITATION·A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Conditions: Myositis · Active Idiopathic Inflammatory Myopathy · Dermatomyositis · Polymyositis·Matched via name phrase
- NCT06154252·RECRUITING·RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Conditions: Idiopathic Inflammatory Myopathy · Dermatomyositis · Anti-Synthetase Syndrome · Immune-Mediated Necrotizing Myopathy·Matched via name phrase
- NCT06685042·RECRUITING·Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
Conditions: Lupus Erythematosus, Systemic · System; Sclerosis · ANCA Associated Vasculitis · Dermatomyositis·Matched via name phrase
- NCT06888973·ENROLLING BY INVITATION·Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases
Conditions: Rheumatoid Arthritis · Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis · Ankylosing Spondylitis (AS)·Matched via name phrase
- NCT06455449·RECRUITING·A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Conditions: Polymyositis, Dermatomyositis·Matched via name phrase
- NCT06347718·RECRUITING·CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Conditions: Systemic Lupus Erythematosus · Systemic Sclerosis · Dermatomyositis · Polymyositis·Matched via name phrase
- NCT06698796·RECRUITING·A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Conditions: Dermatomyositis · Polymyositis·Matched via name phrase
- NCT07122648·NOT YET RECRUITING·Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis
Conditions: Polymyositis · Dermatomyositis·Matched via name phrase
Observational and natural-history studies
21 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07374107·RECRUITING·MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Conditions: IBM · IIM · Myositis · Inflammatory Myopathy·Matched via name phrase
- NCT06339957·RECRUITING·Rheumatology Diet Study
Conditions: Diet Habit · Rheumatologic Disease · Autoimmune Diseases · Rheumatoid Arthritis·Matched via name phrase
- NCT00017914·RECRUITING·Adult and Juvenile Myositis
Conditions: Dermatomyositis · Polymyositis · Inclusion Body Myositis·Matched via name phrase
- NCT01276470·RECRUITING·Environmental Risk Factors for the Anti-synthetase Syndrome
Conditions: Myositis · Dermatomyositis · Polymyositis · Juvenile Dermatomyositis·Matched via name phrase
- NCT04402086·RECRUITING·Rheumatology Patient Registry and Biorepository
Conditions: Rheumatic Diseases · Adult Onset Still Disease · Ankylosing Spondylitis · Psoriatic Arthritis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Polymyositis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Polymyositis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 45 interventional · 21 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: PM
Confidence reasoning
- Preferred label is short or not clearly distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T15:06:16.141Z
